Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Immune senescence and vaccines to prevent herpes zoster in older persons.

Levin MJ.

Curr Opin Immunol. 2012 Aug;24(4):494-500. doi: 10.1016/j.coi.2012.06.002. Epub 2012 Aug 2. Review.

PMID:
22857823
2.

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.

3.

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.

Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H.

Vaccine. 2000 Feb 25;18(16):1700-6.

PMID:
10689152
4.

Varicella zoster virus vaccines: effective, but concerns linger.

Liesegang TJ.

Can J Ophthalmol. 2009 Aug;44(4):379-84. doi: 10.3129/i09-126. Review.

PMID:
19606157
5.

Zoster vaccine: current status and future prospects.

Oxman MN.

Clin Infect Dis. 2010 Jul 15;51(2):197-213. doi: 10.1086/653605. Review.

6.

VZV T cell-mediated immunity.

Weinberg A, Levin MJ.

Curr Top Microbiol Immunol. 2010;342:341-57. doi: 10.1007/82_2010_31. Review.

PMID:
20473790
7.

Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications.

Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN.

Clin Infect Dis. 2013 Apr;56(8):1085-93. doi: 10.1093/cid/cis1208. Epub 2013 Feb 13.

8.

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.

Sanford M, Keating GM.

Drugs Aging. 2010 Feb 1;27(2):159-76. doi: 10.2165/10489140-000000000-00000. Review.

PMID:
20104941
9.

Varicella zoster vaccines and their implications for development of HSV vaccines.

Gershon AA.

Virology. 2013 Jan 5;435(1):29-36. doi: 10.1016/j.virol.2012.10.006. Review.

10.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

11.

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A.

J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9.

PMID:
26452397
12.
13.

[Possibility of prevention of herpes zoster by use of varicella vaccine].

Kawano S, Terada K, Yagi Y, Kataoka N.

Kansenshogaku Zasshi. 1998 Jul;72(7):714-9. Japanese.

PMID:
9745221
14.

Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.

Berger R, Luescher D, Just M.

Postgrad Med J. 1985;61 Suppl 4:143-5.

PMID:
3014472
15.

Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect.

Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR.

J Infect Dis. 1998 Nov;178 Suppl 1:S109-12.

16.

Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, Haas JG, Johnston C, Wald A, Koelle DM.

J Infect Dis. 2015 Oct 1;212(7):1022-31. doi: 10.1093/infdis/jiv164. Epub 2015 Mar 17.

PMID:
25784732
17.

A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.

Holcomb K, Weinberg JM.

J Drugs Dermatol. 2006 Oct;5(9):863-6. Review.

PMID:
17039651
18.

Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.

Distler E, Schnürer E, Wagner E, von Auer C, Plachter B, Wehler D, Huber C, Kolbe K, Meyer RG, Herr W.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1417-24. doi: 10.1016/j.bbmt.2008.09.004.

19.

Herpes zoster virus vaccine.

Woolery WA.

Geriatrics. 2008 Oct;63(10):6-9. Review.

PMID:
18828650
20.

Prevention strategies for herpes zoster and post-herpetic neuralgia.

Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L.

J Clin Virol. 2010 May;48 Suppl 1:S14-9. doi: 10.1016/S1386-6532(10)70004-4. Review.

PMID:
20510262
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk